Further studies of the PNPLA3 polymorphism in the context of NASH in humans and its mechanism of action are required, to confirm whether murine models with this genetic mutation are good preclinical models of NASH. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatohepatitis.